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Abstract
Introduction Primary Sjögren’s syndrome (pSS) is an autoimmune disease, characterized by lymphocytic infiltration of 
exocrine glands and other organs, resulting in dry eye, dry mouth and extraglandular systemic findings.
Objective To explore the association of severe or very severe dry eye with extraocular involvement in patients diagnosed 
with primary Sjögren’s syndrome.
Methods SJOGRENSER registry is a multicenter cross-sectional study of pSS patients. For the construction of our main 
variable, severe/very severe dry eye, we used those variables that represented a degree 3–4 of severity according to the 2007 
Dry Eye Workshop classification. First, bivariate logistic regression models were used to identify the effect of each independ-
ent variable on severe/very severe dry eye. Secondly, multivariate analysis using regression model was used to establish the 
independent effect of patient characteristics.
Results Four hundred and thirty-seven patients were included in SJOGRENSER registry; 94% of the patients complained 
of dry eye and 16% developed corneal ulcer. Schirmer’s test was pathological in 92% of the patients; 378 patients presented 
severe/very severe dry eye. Inflammatory articular involvement was significantly more frequent in patients with severe/very 
severe dry eye than in those without severe/very severe dry eye (82.5 vs 69.5%, p = 0,028). Inflammatory joint involvement 
was associated with severe/very severe dry eye in the multivariate analysis, OR 2.079 (95% CI 1.096–3.941).
Conclusion Severe or very severe dry eye is associated with the presence of inflammatory joint involvement in patients with 
pSS. These results suggest that a directed anamnesis including systemic comorbidities, such as the presence of inflammatory 
joint involvement or dry mouth in patients with dry eye, would be useful to suspect a pSS.
Keywords Dry eye syndromes · Sjögren’s syndrome · Joints · Schirmer’s test
Introduction
Primary Sjögren’s syndrome (pSS) is the second most com-
mon autoimmune disease, of unknown etiology and slow 
progression, with a prevalence of 0.1–5% in the general 
population. It affects predominantly the female sex and is 
characterized by lymphocytic infiltration of exocrine glands 
and other organs, resulting in dry eye and dry mouth and 
extraglandular systemic findings, such as pain, myalgia 
or polyarthralgia, among others [1]. The condition has a 
marked negative impact on health-related quality of life and 
social functioning [2].
Dry eye is one of the most common problems encoun-
tered by eye care practitioners globally. In the USA alone, 
an estimated 16.4 million adults aged ≥ 18 years have dry 
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eye disease (DED) [3]. DED is a multifactorial disease 
with a variety of risk factors identified, including the asso-
ciation of several systemic diseases such as pSS. In 2007, 
the International Dry Eye Workshop (DEWS) compiled 
an evidence-based review of the methods used to evaluate, 
diagnose and manage DED [4]. In 2016, the Tear Film and 
Ocular Surface Society (TFOS) DEWS II [5] has identified 
two predominant classes of dry eye: aqueous–deficient and 
evaporative [6]. Aqueous-deficient dry eye is subcatego-
rised into pSS-related dry eye and non-pSS dry eye. Of 
individuals with a significant aqueous deficient dry eye, 
10% are likely to have Sjögren síndrome [7]. In harmony 
of the classification criteria by American-European con-
sensus group (AECG) [8], pSS consists of the occurrence 
of aqueous deficient dry eye syndrome in combination 
with symptoms of dry mouth, in the presence of autoanti-
bodies, evidence of reduced salivary secretion and with a 
positive focus score on minor salivary gland biopsy.
Because dry eye is one of the most common symptoms 
of pSS, patients often first seek care from eye care provid-
ers, who can potentially play a key role in reducing the 
time from symptom onset to diagnosis. In SJOGRENSER 
registry the delay in diagnosis from the onset of the first 
symptoms is substantial, with a median age of the first 
symptom of 47 years and a median age at diagnosis of 
50 years [9]. Nevertheless, screening is challenging, as 
there is currently no universal standard regarding which 
dry eye patients should undergo a comprehensive evalua-
tion for pSS, there is limited evidence regarding specific 
ocular signs that in isolation can reliably distinguish pSS-
related from non-SS-related dry eye. The aim of this study 
is to explore factors associated with severe or very severe 
dry eye in patients with pSS. Identification of variables 
that are associated with the development of pSS may con-
tribute to earlier diagnosis and treatment of the disease, 




This is a descriptive cross-sectional study of pSS patients 
fulfilling 2002 AECG criteria [8], from 33 Spanish rheu-
matology departments participating in SJOGRENSER 
study, a Systemic Autoimmune Disease Group Project of 
the Spanish Society of Rheumatology. The objectives and 
methodology of the SJOGRENSER Registry have been 
published previously [9].
Study population
Four hundred and thirty-seven patients with pSS were 
included in the SJOGRENSER Registry. To avoid any selec-
tion bias, patients were selected by randomization from an 
anonymized list provided by every unit. Data were collected 
by reviewing clinical records and interviewing patients. The 
exclusion criteria were also based on the AECG criteria; 
in addition, we excluded patients younger than 18 years’ 
old or individuals unable to provide informed consent. 
This registry was performed between 2013 and 2014 over a 
12-month period of time. An online monitored control of all 
the information and an on-site monitored control of a per-
centage of centers randomly selected were used to clarify all 
inconsistencies, missing values, and discrepancies. A signed 
informed consent was obtained from the patients and the eth-
ics committees of the hospitals approved the study.
Variables
The sociodemographic variables from SJOGRENSER regis-
try included for this article were age, sex, time of evolution 
of disease and clinical variables like systemic manifestations 
(Table 1) and the presence of ocular symptoms included in 
the subjective AECG criteria: (1) Have you had daily, persis-
tent, troublesome dry eyes for more than 3 months?, (2) Do 
you have a recurrent sensation of sand or gravel in the eyes? 
(3) Do you use tear substitutes more than 3 times a day? 
[10]. We also included dry eye complications like corneal 
ulcers and, serological parameters like ANA (antinuclear 
antibodies), RF (Rheumatoid Factor) and Anti-Ro/Anti-
La, and labial salivary gland (LSG) biopsy; in our cohort, 
we collected the Chisholm and Mason grades (considering 
as pathological 3 and 4 grades, since they correspond to 
one or more lymphocyte infiltration foci respectively, focus 
score ≥ 1). The standardized objective measurement for dry 
eye collected were Schirmer’s I test (pathological accord-
ing to AECG criteria:≤5 mm/5 min) and ocular stains. 
Data from pSS related symptoms and activity index, were 
collected using the EULAR Sjögren’s Syndrome Patient 
Reported Index (ESSPRI) [11] and EULAR Sjögren’s Syn-
drome Disease Activity Index (ESSDAI) [12]. The pharma-
cological and surgical therapeutic options included in this 
article were autologous sera, contact lenses, punctual occlu-
sion, Stenon conduit bypass and palpebral cleft reduction.
To define our main variable, “severe or very severe dry 
eye”, we included the subjective and objective criteria of 
the TFOS DEWS I consensus classification of 2007 [4]. 
They recommend dry eye treatments based on the level 
of disease severity (LDS). The severity grading scheme 
contains 4 LDS based on signs and visual symptoms, 
among them: conjunctival injection, conjunctival stain-
ing, corneal and tear signs, lid and meibomian glands, tear 
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break-up time and Schirmer score. Not all of these vari-
ables were collected in our registry, so for the construc-
tion of our main variable, we used those variables present 
in our cohort that represented a degree 3 or 4 of severity 
(severe or very severe dry eye, respectively) according to 
the TFOS DEWS classification for dry eye. Those vari-
ables were: the pathological Schirmer score (corresponds 
with a 3 LDS), corneal ulcers (correspond with a 4 LDS), 
autologous sera and contact lenses (corresponds with a 
3 LDS) and, Stenon conduit bypass and palpebral cleft 
reduction (corresponds with a 4 LDS).
Finally, in those patients with dry eye (any positive 
response to the 3 dryness questions included in the AECG 
criteria), the selected variables to define “severe or very 
severe dry eye” were: Schirmer score and/or corneal ulcers 
and/or autologous sera and/or contact lenses and/or Stenon 
conduit bypass and/or palpebral cleft reduction. We did 
not consider ocular stains because of the high percentage 
of losses in the collection of this variable by researchers. 
Blepharitis was not selected because it appears on the dry 
eye severity scale at all levels; the frequency of appear-
ance of blepharitis is not collected in the SJOGREN-SER 
cohort. Punctual occlusion has not been included because 
in SJOGREN-SER registry there is no difference between 
transient punctual occlusion (2 LDS) and permanent (4 
LDS).
Statistical analysis
We developed descriptive analyses, using bivariate cor-
relations and regression analysis to model the association 
between “severe or very severe dry eye” and clinical vari-
ables recorded in SJOGRENSER. The descriptive anal-
ysis consists of median and interquartile ranges, which 
were used to describe numeric variables. Proportions 
were used for categorical variables. Chi-Square test was 
used for categorical variables and Kruskal Wallis test for 
numeric variables. Statistical significance was considered 
as a p < 0.05.
First, bivariate logistic regression models were used to 
identify the effect of each independent variable on severe 
or very severe dry eye. Second, multivariate analysis using 
regression model was used to establish the independent 
effect of patient characteristics associated with the depend-
ent variable. The model included odds ratio (OR), 95% 
confidence intervals and associated statistical significance. 
Sex, age and ESSDAI score were considered as adjustment 
variables in the final regression model.
The analysis was performed using SPSS 21.0 for Win-
dows (SPSS Inc., Chicago, Illinois, USA).
Table 1  Baseline characteristics 
of SjögrenSER patients 
according to the severity in the 
dry eye
* p < 0.05
Variables Dry eye not severe 
(n = 32)
Severe/very severe dry 
eye (n = 378)
p
Age at diagnosis, mean (SD) 49.33 (13.9) 50.56 (12.7) 0.195
Sex, women n (%) 57 (96.6) 359 (95.0) 0.585
Index
 ESSPRI, mean (SD) 5.20 (2.5) 5.28 (2.3) 0.980
 ESSDAI, mean (SD) 5 (7) 5 (5) 0.854
Systemic manifestations
 Inflammatory articular involvement n (%) 41 (69.5) 312 (82.5) 0.028*
 Pulmonar involvement n (%) 6 (10.3) 37 (9.8) 0.895
 Renal involvement n (%) 6 (10.3) 33 (8.7) 0.688
 Central nervous system involvement n (%) 5 (8.6) 29 (7.7) 0.802
 Glandular inflammation n (%) 21 (35.6) 121 (32.0) 0.585
 Peripheral nervous system involvement n (%) 5 (8.6) 34 (9.0) 0.926
 Digestive involvement n (%) 11 (18.6) 48 (12.7) 0.214
 Hematologic involvement n (%) 31 (52.5) 213 (56.3) 0.584
 Pathological labial salivary gland biopsy (focus 
score ≥ 1) n (%)
26 (44.1) 107 (28.3) 0.014*
Analysis
 ANA + n (%) 58 (98.3) 366 (96.8) 0.534
 RF + n (%) 39 (72.2) 245 (65.7) 0.341
 AntiRo + n (%) 58 (98.3) 351 (92.9) 0.112




Four hundred and thirty-seven patients were included 
in SJOGRENSER registry [female gender 95%; median 
age 58 (50.02–67.98) years]. Mean time of evolution of 
the disease in the cohort was 8.3 years. All patients were 
ANA positive, 94% were AntiRo +, 67% were AntiLa +, 
and 65% RF positive. ESSDAI mean score was 2 (0–4, 
P25–P75) and the median in ESSPRI index was 5.3 
(p25–p75, 3.67-7) in the full registry. 94% of the patients 
in SJOGRENSER registry complained of daily, persistent, 
troublesome dry eye, 92% had sensation of sand and, 16% 
developed corneal ulcer.
In the full cohort, Schirmer’s test was performed in 402 
patients and was pathological in 371 patients (92%). Rose 
Bengal staining test was performed in 144 patients, green 
lissamine and fluorescein staining tests were performed in 
19 and 81 patients respectively. LSG biopsy was obtained 
in 193 patients, 133 of them fulfilling grades 3 or 4 of 
Chisholm-Mason classification (69%). The use of autol-
ogous sera was 14%, contact lenses 2%, Stenon conduit 
bypass 0.23% and palpebral cleft reduction 0.23%.
378 patients (86.5%) presented severe or very severe dry 
eye; 95% were women and the median age was 50 years. 
Mean time of evolution of disease was 8.51 years. ESS-
DAI mean score in this subgroup was 5 and the median in 
ESSPRI index was 5.28. 312 patients developed inflam-
matory articular involvement, according to the definition 
of the ESSDAI index: all of them reported inflammatory 
joint pain and 132 also presented arthritis. The baseline 
characteristics of the patients according to the severity of 
the dry eye are shown in Table 1. Inflammatory articular 
involvement was significantly more frequent in patients 
with severe/very severe dry eye (82.5 vs 69.5%, p = 0.028) 
(Table 1). In the descriptive analysis, the pathological LSG 
biopsy was more frequent in individuals with non-severe 
dry eye, however, in the multivariate analysis, no signifi-
cant association was found between this variable and the 
non-severe dry eye. In the bivariate (Table 2) and in the 
multivariate analysis (Table 3), inflammatory joint involve-
ment was a factor associated with severe/very severe dry 
eye, with an OR of 2.079 (95% CI 1.096–3.941) adjusted 
by sex, age, time of evolution of the disease and ESSDAI 
score (Table 3). No relationship was found between severe/
very severe dry eye and the rest of extraglandular mani-
festations (Table 1).
Discussion
The aim of this study was to identify factors associated 
with severe or very severe dry eye in patients with pSS. We 
have found two main findings, first we have found a high 
Table 2  Bivariate analysis 
results
Factors associated with severe dry eye in SSp
Variables Wald OR Confidence interval
Age at diagnosis 0.462 1.007 0.986–1.029
Sex, women 0.295 0.663 0.150–2.923
Time of evolution of SSp 2.291 0.136 0.99–1.085
Index
 ESSPRI 0.061 1.015 0.902–1.143
 ESSDAI 0.014 0.997 0.950–1.047
Systemic manifestations
 Inflammatory articular involvement 5.423 2.075 1.123–3.837
 Pulmonar involvement 0.018 0.940 0.378–2.338
 Renal involvement 0.161 0.829 0.331–2.075
 Central nervous system involvement 0.063 0.881 0.327–2.375
 Glandular inflammation 0.298 0.852 0.479–1.578
 Peripheral nervous system involvement 0.009 1.048 0.392–2.798
 Digestive involvement 1.524 0.635 0.308–1.306
 Hematologic involvement 0.300 1.166 0.673–2.021
 Pathological labial salivary gland biopsy 5.835 0.501 0.286–0.878
Analysis
 ANA + 0.374 0.526 0.067–4.121
 RF + 0.900 0.736 0.391–1.386
 AntiRo + 2.116 0.224 0.030–1.681
 AntiLa + 0.527 0.800 0.438–1.461
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prevalence of severe or very severe dry eye in our popula-
tion of patients with pSS; secondly, we have identified a 
strong association between severe dry eye and inflammatory 
articular involvement. Taking into account that the majority 
of pSS patients first seek medical care for dry eye symptoms, 
that dry eye disease is highly prevalent in the general popu-
lation, and that pSS evaluations are costly, complex, and 
time-consuming, it is of great interest to be able to draw up 
a list of factors associated with severe dry eye, often devel-
oped by pSS patients. At least two ophthalmologic methods 
(Schirmer test and ocular staining) are recommended for the 
evaluation of dry eye. Not all involved patients in this cohort 
had these two tests, so in this sample dry eye is defined as 
severe/very severe with other included criteria. We examined 
the associations of an individual dry eye test result (Schirmer 
test), complications and treatments used in severe dry eye in 
pSS patients, with extraocular characteristics for pSS.
Other authors have also found a relationship between joint 
involvement and dry eye. Paulsen et al. [13] investigated the 
prevalence of dry eye (14.5%) and identified independent 
risk factors in 3285 patients. In the multivariable model, dry 
eye symptoms were associated with arthritis (OR 2.14) in 
patients younger than 50 years. A limitation of the Paulsen’s 
study was that only a few participants reported a history 
of being diagnosed by their doctor as having SS (Sjögren’s 
syndrome). This same cohort was examined years ago by 
Moss et al. (1993–1995) [14], also finding at that time, an 
association between dry eye and arthritis (OR 1.91).
Roh et al. [15] tried to identify systemic comorbidities in 
patients with dry eye syndrome in South Korea (n = 17,364), 
with a prevalence of dry eye of 10.4%. Degenerative arthritis 
(OR 1.57) and rheumatoid arthritis (OR 1.44) were associ-
ated with a significantly higher prevalence of dry eye. One 
limitation of Roh’s study, regarding the topic of interest of 
this article, is that it is not known whether the patients of this 
cohort were evaluated for pSS in a specific way.
Other authors have found a relationship between dry 
eye and other clinical or serological parameters. Liew et al. 
[7] reported a prevalence of SS in patients with clinically 
significant aqueous-deficient dry eye (ADDE) of 11.6%. 
They found that patients with SS had significantly worse 
conjunctival and corneal staining, Schirmer test, and symp-
toms compared with patients without SS; SS was also sig-
nificantly more likely to occur in patients with ANA and RF.
This finding was also noted in the studies of Whitcher 
and colleagues and Lim and collaborators [16, 17]; both 
reported that patients with SS were more likely to be posi-
tive for RF and ANA. These authors belong to the SICCA 
group (Sjögren’s International Collaborative Clinical Alli-
ance) [18]; they evaluated 920 participants and found that 
in the keratoconjunctivitis sicca (KCS) group, the median 
OSS (Ocular Staining Index, contemplated in SICCA clas-
sification criteria 2012) was 5 compared to 9 among those 
with SS-KCS (p < 0.0001). A statistically significant differ-
ence with respect to the Schirmer test reflected a higher level 
of severity in the SS-KCS than in the KCS-only group. In 
2012, Chung et al. also published that serum anti-La anti-
body, serum anti-Ro antibody and tear IL-17 were likely 
strongly involved in the clinical severity of KCS in patients 
with pSS [19]. All patients in the SJOGRENSER registry 
were ANA + and the majority were AntiRo +, so no dif-
ferences could be established between groups using these 
serological parameters.
From the previous cohort (SICCA group), Bunya et al. 
[20] described how to differentiate those patients with dry 
eye with a greater suspicion of SS in a cohort of 3514 indi-
viduals recruited with SS or possible SS, evaluating the rela-
tionship that exists between ocular surface tests and typical 
extraocular manifestations of SS; they found that those with 
an abnormal Schirmer I test or positive ocular stain present 
a significantly higher probability of having a positive LSG 
biopsy or a positive serology.
Many other authors conclude and demonstrate a high 
frequency of associated SS in patients with dry eye [21]. 
Martinez et al., in 2016 [22], studied the frequency and risk 
factors of dry eye among patients in Mexico. The frequency 
of severe dry eye symptoms was found to be between 43 and 
30%. Dry mouth was a risk factor significantly associated 
with increased dry eye symptoms, aqueous tear deficiency, 
and corneal staining and, the presence of arthritis was a risk 
factor associated with meibomian gland dysfunction.
As we have seen, abnormal Schirmer tests are of vital 
importance when SS is suspected in patients with dry eyes. 
The evaluation of the symptoms is essential in the assess-
ment of dry eye, however, the standard procedure in the 
usual clinical practice for DED diagnosis includes the per-
formance of at least one objective test [23]. The possible 
diagnostic tools in the evaluation of tear film disorders are 
multiple, however, the preferred ones are patient history/
Table 3  Multivariate analysis results
Factors associated with severe dry eye in SSp
Variables Wald OR Confidence interval
Age at diagnosis 1.901 1.016 0.993–1.039
Sex, women 1.310 0.252 0.039–2.342
Time of evolution of the disease 3.323 1.046 0.997–1.098
Index





 Labial salivary gland biopsy
  Focus score ≥ 1 2.451 0.519 0.229–1.179
  Unknown 0.039 1.079 0.504–2.309
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dry eye questionnaires, tear break-up time, ocular surface 
staining and Schirmer test [24, 25]. Sullivan et al., in 2014, 
concluded that the information on the ocular surface pro-
vided by each test is different, and demonstrated that for the 
diagnosis and treatment of DED not only the symptoms of 
the patient can be taken into account [26].
With regard to the lack of a gold-standard for the severe 
dry eye diagnosis, the multinational ODISSEY European 
Consensus Group, formed by ophthalmologists from differ-
ent countries, established in 2014 an algorithm to identify 
the most relevant tools in the evaluation of the ocular sur-
face and therefore its severity. This panel recommended that 
only two criteria, evaluation of symptoms and evaluation of 
the ocular surface with fluorescein staining, were adequate 
to assess severity in most patients. Not forgetting that this 
article focuses exclusively on patients with pSS, the authors 
of this group also described in their study that the Schirmer 
test is the quantitative test available to measure the lacrimal 
flow and therefore the maximum capacity of secretion of the 
lacrimal glands, key dysfunction in this disease; they added 
that this method is well established, easy to use, commonly 
accepted and available, safe and efficient and usually well 
tolerated (except in the severe DED) [27].
Our findings suggest that inflammatory articular involve-
ment is significantly associated with severe dry eye in pSS 
patients, an assessment that can be made easily with a simple 
anamnesis like “do you have arthritis or inflammatory joint 
pain?”. The ESSDAI definition of inflammatory joint pain is 
“pain in hands/wrists/ankles and/or feet and stiff in the morn-
ing for at least 30 min” and the ESSDAI definition of arthri-
tis is “joint inflammation”. pSS patients with inflammatory 
articular involvement have twice risk of severe dry eye in 
pSS patients compared to those who have no inflammatory 
joint involvement in our cohort. For ophthalmologists, a 
more careful interview for systemic comorbidities in patients 
with dry eye, like the presence of inflammatory articular 
involvement, dry mouth or other systemic manifestations, is 
possibly much easier, non-aggressive, faster and less expen-
sive than performing other actions such as a blood test in 
search of specific antibodies or perform a minor salivary 
gland biopsy. The results of this study support calling for 
an increased index of suspicion for ophthalmologists caring 
for dry eye, and the recommendation that the presence of 
SS should be assessed in all patients with clinically signifi-
cant DED. It is also of great interest that Schirmer test is an 
easy and a critical test that should always be included when 
screening dry eye patients to determine whether a further 
evaluation for pSS is warranted.
Undoubtedly, the typical antibodies of pSS and the 
LSG biopsy are two very important characteristics of 
pSS patients. However, they are tests that demand greater 
effort, cost, complexity, and invasion for the patient. An 
adequate anamnesis guided by the ophthalmologist is 
simple and fast and can give a lot of important informa-
tion suspicious of pSS in the patient with severe dry eye. 
Therefore, we suggest a simple algorithm for suspected 
diagnosis of pSS, based on the use of the Schirmer test and 
an anamnesis guided to the patient with dry eye, so that the 
ophthalmologist can make an initial screening and know 
which patient with dry eye should be referred to the rheu-
matologist (Fig. 1). This algorithm should be considered 
as a proposal pending of consensus with more experts, 
OPHTHALMOLOGIST
Schirmer test (≤5 mm / 5 min) 
Patient with Dry Eye Symptoms
2 items of:
American/European Consensus Group (AECG) 





AECG Classification Criteria of 2002
Suspected Systemic Disease 
Refer to the RHEUMATOLOGIST 
(suspected pSS or other systemic disease)
We can extend the anamnesis:
-Other systemic manifestations?
-Other tests for the evaluation of tear film:
Ocular Surface Staining
(Lissamine Green and Fluorescein)
-*Analysis: 
RF positive + ANA ≥1/320
Anti-Ro/La
*Ask the patient if his / her 
primary care doctor or other 
doctor has performed an 
analysis to investigate this 
process
ESSDAI definition: 
*Inflammatory Arthralgias: pain in hands/wrists/ankles 
and/or feet + stiff in the morning for at least 30 minutes.
*Arthritis: joint inflammation
The patient meets the SICCA
(Sjögren's International Collaborative Clinical Alliance)
Classification Criteria of pSS
If OSS ≥3
The patient meets the AECG 




and/or corneal ulcers and/or autologous sera 
and/or contact lenses and/or Stenon conduit 
bypass and/or palpebral cleft reduction
Fig. 1  Algorithm for suspected diagnosis of pSS, based on the use of the Schirmer test and an anamnesis guided to the patient with dry eye
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ophthalmologists, and rheumatologists, and validated in 
the future with an ad hoc project.
A possible limitation of our study was the small number 
of patients in the non-severe dry eye group compared with 
the severe/very severe dry eye group (32/378); this can 
be explained by the high number of patients with dry eye 
(94%) and, by the high number of patients with pathologi-
cal Shirmer test performed (371/402, 92%) (score equiva-
lent to a severe dry eye); 85% of the patients recruited in 
this cohort (371/437) had severe/very severe dry eye at the 
time of inclusion in SJOGRENSER registry because they 
had a Schirmer test ≤ 5 mm. Another possible limitation 
could have been the failure to be able to do a complete 
study evaluating other objective tests of ocular dryness, 
such as ocular staining, due to the high percentage of 
losses in this variable.
In summary, for ophthalmologists, asking about the 
presence of inflammatory articular involvement and dry 
mouth is possibly much easier, non-aggressive, faster and 
less expensive, than performing other actions such as a 
blood test in search of specific antibodies or perform a 
minor salivary gland biopsy. A large prospective study is 
needed to estimate the association of other factors with 
dry eye. The possibility of a screening algorithm involv-
ing both ophthalmologist and rheumatologist should be 
tested in future studies. If a pSS is suspected, the oph-
thalmologist could refer the patient to the rheumatologist 
to complete the tests that the patient needs and for a right 
follow-up and systematic treatment, always in collabora-
tion with the ophthalmologist, for multidisciplinary con-
trol of dry eye.
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